Emerging manufacturers engagements in the COVID −19 vaccine research, development and supply

•Broad research and development is key to achieving an effective safe COVID-19 vaccine.•Currently 19 Network members engaged in research & development of 22 COVID-19 vaccines.•Collectively 37 Network manufacturers supply around 3.5 billion vaccine doses annually.•Existing manufacturing capabilit...

Full description

Saved in:

Bibliographic Details
Published in:	Vaccine Vol. 38; no. 34; pp. 5418 - 5423
Main Authors:	Pagliusi, Sonia, Jarrett, Stephen, Hayman, Benoit, Kreysa, Ulrike, Prasad, Sai D., Reers, Martin, Hong Thai, Pham, Wu, Ke, Zhang, Youn Tao, Baek, Yeong Ok, Kumar, Anand, Evtushenko, Anatoly, Jadhav, Suresh, Meng, Weining, Dat, Do Tuan, Huang, Weidan, Desai, Samir
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 22-07-2020 Elsevier Limited Elsevier Science
Subjects:	Antigens Biomedical Research - organization & administration Clinical Trials as Topic Coronavirus Infections - immunology Coronavirus Infections - prevention & control Coronaviruses COVID-19 COVID-19 Vaccines Deoxyribonucleic acid Developing countries DNA Drug Industry - organization & administration Hepatitis Humans Immunization Influenza International Cooperation International regulations LDCs Manufacturers Manufacturing Measles Meningitis Pandemics Pandemics - prevention & control Pneumonia, Viral - prevention & control Polls & surveys Production capacity R&D Research & development Rubella Severe acute respiratory syndrome coronavirus 2 Tetanus Tropical diseases Vaccines Viral infections Viral Vaccines - immunology Viral Vaccines - supply & distribution Viruses World Health Organization
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•Broad research and development is key to achieving an effective safe COVID-19 vaccine.•Currently 19 Network members engaged in research & development of 22 COVID-19 vaccines.•Collectively 37 Network manufacturers supply around 3.5 billion vaccine doses annually.•Existing manufacturing capabilities can accelerate the availability of COVID vaccines.•Deploying available vaccine production capacity, will save time, resources and lives. The World Health Organization declared the COVID-19 disease as a pandemic requiring a rapid response. Through online search, direct communication with network members and an internal survey, engagements of developing countries’ vaccine manufacturers’ network members in the research and development of COVID-19 vaccines and their capacities in the manufacturing, fill-finish and distribution of vaccines were assessed. Currently, 19 network members engaged in research and development of COVID-19 vaccines, using six principal technology platforms. In addition, an internal survey showed that the number of vaccines supplied collectively by 37 members, in 2018–19, was about 3.5 billion doses annually. Almost a third of network members having vaccines prequalified by the World Health Organization comply with international regulations and mechanisms to distribute vaccines across borders. The use of existing manufacturing, fill-finish and distribution capabilities can support an efficient roll-out of vaccines against COVID-19, while maintaining supply security of existing vaccines for on-going immunization programmes.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2020.06.022